Insmed Incorporated

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About INSM

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. 

CEO
William H. Lewis
CEOWilliam H. Lewis
Employees
1,271
Employees1,271
Headquarters
Bridgewater, New Jersey
HeadquartersBridgewater, New Jersey
Founded
1988
Founded1988
Employees
1,271
Employees1,271

INSM Key Statistics

Market cap
33.23B
Market cap33.23B
Price-Earnings ratio
-24.66
Price-Earnings ratio-24.66
Dividend yield
—
Dividend yield—
Average volume
2.25M
Average volume2.25M
High today
$156.52
High today$156.52
Low today
$152.23
Low today$152.23
Open price
$152.44
Open price$152.44
Volume
529.20K
Volume529.20K
52 Week high
$212.75
52 Week high$212.75
52 Week low
$60.40
52 Week low$60.40

Stock Snapshot

As of today, Insmed Incorporated(INSM) shares are valued at $155.80. The company's market cap stands at 33.23B, with a P/E ratio of -24.66.

On 2026-02-05, Insmed Incorporated(INSM) stock moved within a range of $152.23 to $156.52. With shares now at $155.80, the stock is trading +2.3% above its intraday low and -0.5% below the session's peak.

Trading activity shows a volume of 529.2K, compared to an average daily volume of 2.25M.

The stock's 52-week range extends from a low of $60.40 to a high of $212.75.

The stock's 52-week range extends from a low of $60.40 to a high of $212.75.

INSM News

TipRanks 2d
Insmed’s ENCORE Trial Reaches Key Milestone in MAC Lung Infection

Insmed (INSM) announced an update on their ongoing clinical study. Study Overview: Insmed’s ENCORE trial (NCT04677569) is a phase 3 study testing whether addin...

Simply Wall St 5d
Should TPIP’s New Clinical Data and Analyst Coverage Require Action From Insmed Investors?

Insmed recently announced that it will present four abstracts on its treprostinil palmitil inhalation powder (TPIP) program for pulmonary arterial hypertension...

Should TPIP’s New Clinical Data and Analyst Coverage Require Action From Insmed Investors?
Simply Wall St 6d
Insmed Valuation Check As TPIP Data And New Barclays Coverage Refocus Attention On Pipeline

Insmed (INSM) is back in focus after the company flagged four upcoming presentations on its treprostinil palmitil inhalation powder program at the PVRI 2026 con...

Insmed Valuation Check As TPIP Data And New Barclays Coverage Refocus Attention On Pipeline

Analyst ratings

95%

of 22 ratings
Buy
95.5%
Hold
4.5%
Sell
0%

People also own

Based on the portfolios of people who own INSM. This list is generated using Robinhood data, and it’s not a recommendation.
Taiwan Semiconductor Manu…
Micron Technology
Broadcom
Robinhood Markets
Palantir Technologies
Uber

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.